12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sphingomab: Phase Ib discontinued

Lpath and partner Pfizer Inc. (NYSE:PFE, New York, N.Y.) agreed to discontinue the Phase Ib PEDigree trial of iSONEP to focus on the Phase IIa Nexus trial in PED secondary to wet age-related macular degeneration (AMD). Lpath said that under the amended terms of its deal with Pfizer, Lpath can elect to continue the PEDigree trial at any time but would be responsible for any related costs. Lpath...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >